Compare ADMA Biologics Inc (ADMA) vs iShares International Treasury Bond ETF (IGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs iShares International Treasury Bond ETF — how do they compare? ADMA Biologics Inc trades at $9.85 (market cap $2.22B), while iShares International Treasury Bond ETF trades at $41.32. The key difference: iShares International Treasury Bond ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | IGOV | |
|---|---|---|
Market Cap | $2.22B | — |
Sector | Health | — |
52-Week High | $20.38 | $43.09 |
52-Week Low | $7.60 | $40.35 |
Enterprise Value | $2.29B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
IGOV trades at $41.13, down 0.15% on the day, with a bullish technical signal driven by moving averages despite neutral oscillators. The stock shows consolidated trading near key support at $41. Financial data remains limited, but recent news highlights significant exposure to global bond market volatility through its ETF structure.
The outlook is clouded by interest rate sensitivity and inflationary pressures, posing downside risks. Investment appeal hinges on macroeconomic stability, while the primary opportunity lies in potential yield curve normalization benefiting long-duration assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →
